Other LMNA gene mutations, such as Dunnigan-type familial partial lipodystrophy (FPLD2), can lead to proatherogenic metabolic disturbances such as dyslipidemia, hyperinsulinemia, hypertension and diabetes. The gene discussed is LMNA; the disease is familial partial lipodystrophy, Dunnigan type.